Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Up 101.0% in February

Minerva Neurosciences, Inc. (NASDAQ:NERV) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 42,000 shares, a growth of 101.0% from the January 31st total of 20,900 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily volume of 41,600 shares, the short-interest ratio is currently 1.0 days.

Minerva Neurosciences Price Performance

Shares of NASDAQ NERV traded down $0.03 during mid-day trading on Friday, reaching $1.67. 18,703 shares of the company’s stock were exchanged, compared to its average volume of 47,113. The firm has a 50-day moving average price of $2.14 and a two-hundred day moving average price of $2.37. The firm has a market capitalization of $11.68 million, a price-to-earnings ratio of -3.80 and a beta of 0.12. Minerva Neurosciences has a 52 week low of $1.64 and a 52 week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. As a group, sell-side analysts forecast that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NERV shares. StockNews.com began coverage on shares of Minerva Neurosciences in a research report on Sunday. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC raised its position in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.